Immunome, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 106.81 million compared to USD 36.9 million a year ago. Basic loss per share from continuing operations was USD 5.38 compared to USD 3.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.61 USD | +0.71% | +0.97% | +45.89% |
02/05 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
30/04 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.89% | 929M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023